New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:02 EDTBDSI, ENDPBioDelivery Sciences could be bought by Endo, says Summer Street
Summer Street sees shares of BioDelivery Sciences (BDSI) heading to the $15 level on positive buprenorphine data in July, a drug the company partners with Endo (ENDP). The firm notes Endo could owe up to $70M in milestones to BioDelivery, but it finds it more likely that Endo buys BioDelivery outright. Summer Street keeps a Buy rating on the stock with a $20 price target.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2015
15:33 EDTENDPEndo confirms court ruling upholding OPANA ER intellectual property
Subscribe for More Information
14:17 EDTENDPEndo jumps 2% after Bloomberg says successful in Opana patent challenge
Subscribe for More Information
14:15 EDTENDPEndo successful in blocking Opana generic until 2023, Bloomberg reports
Subscribe for More Information
August 13, 2015
09:20 EDTBDSIOn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTBDSIBioDelivery Sciences' new Onsolis formulation approved by FDA
BioDelivery Sciences announced the approval by the FDA of a Supplemental New Drug Application for a new formulation of Onsolis CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. The new formulation was submitted to address previously announced appearance-related changes. Early this year, BDSI entered into an assignment and revenue sharing agreement with its partner for Onsolis, Meda Pharmaceuticals, to return the marketing authorization back to BDSI and the right to seek marketing authorizations for Onsolis in the U.S., Canada and Mexico. Meda retains the rights to Onsolis outside the U.S., where it is marketed in the E.U. as Breakyl. Onsolis is separately licensed by BDSI in Taiwan and South Korea.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use